Senetek Retains The Investor Relations Group of New York

Senetek, PLC (OTCBB: SNTKY), a life sciences product development
company targeting the science of aging, has retained The Investor
Relations Group, Inc. (IRG), based in New York City, to serve as its
financial relations and corporate communications firm.

Frank J. Massino, Chief Executive Officer of Senetek, commented,
"We made significant progress on our business plan this past year, and
we look forward to The Investor Relations Group playing an integral
role in ensuring Senetek's story and recent developments reach
shareholders and investors, as well as the trade and consumer media,"
He continued, "We believe IRG will help us deliver our Company's
message more effectively and ultimately raise the profile of Senetek
to the investment community."

Dian Griesel, President and CEO of The Investor Relations Group
said, "IRG will strive to increase investor awareness of Senetek
within the U.S. market by introducing the Company and its management
to pre-qualified investment professionals and both financial and trade
publications."

About The Investor Relations Group, Inc.

The Investor Relations Group, Inc., (IRG) founded in 1996,
represents select publicly traded companies, with a unique
specialization for assisting those in the small-cap sector. IRG
arranges one-on-one meetings for its portfolio companies with
pre-qualified money managers handling investment portfolios that range
from $10 million to $10 billion+ selected from its proprietary contact
base of over 33,000 qualified fund managers who have an investing
history in small-cap stocks. IRG is a full-service corporate
communications company offering services for its portfolio companies
that include writing all press releases and shareholder communications
and serving as primary contact for the investing community. IRG also
houses a full-service public relations arm that specializes in
building awareness of its companies within the financial and trade
media, as well as the public at large. For further information, please
visit the company's website at www.investorrelationsgroup.com.

About Senetek PLC

Senetek PLC (OTCBB: SNTKY) is a life sciences product development
company with a portfolio of intellectual properties targeting the
science of aging, including skincare and dermatological therapeutics,
erectile dysfunction and nutrition. Kinetin, Senetek PLC's lead
commercial product, is currently licensed and marketed by 10
pharmaceutical and cosmeceutical companies, including Valeant
Pharmaceuticals International and The Body Shop. In addition, the
Company has entered into an exclusive global license with Valeant for
Senetek's proprietary anti-aging skincare compound, Zeatin, has
entered into exclusive licenses for Europe and North America,
respectively, for its patented combination drug treatment for erectile
dysfunction, Invicorp(R), has an exclusive manufacturing
distributorship for its proprietary diagnostic monoclonal antibodies,
and recently sold, with retained rights of profit participation, its
patented drug delivery system, Reliaject(R).

For additional information, please visit Senetek PLC's Web site at
http://www.senetekplc.com

Safe Harbor Statement

This news release contains statements that may be considered
'forward-looking statements' within the meaning of the Private
Securities Litigation Reform Act, including those that might imply
commercial potential and successful evaluation and development of new
compounds. Forward-looking statements by their nature involve
substantial uncertainty, and actual results may differ materially from
those that might be suggested by such statements. Important factors
identified by the Company that it believes could result in such
material differences are described in the Company's Annual Report on
Form 10-K/A for the year 2005. However, the Company necessarily can
give no assurance that it has identified or will identify all of the
factors that may result in any particular forward-looking statement
materially differing from actual results, and the Company assumes no
obligation to correct or update any forward-looking statements which
may prove to be inaccurate, whether as a result of new information,
future events or otherwise.